What is Fragment 176-191?

Fragment 176-191 is a peptide that is a modified version of amino acids 176-191.  Its molecular formula is C78H125N23O23S2, and its molecular mass is 1817.12.  It is occasionally referred to by alternate names, such as:

  • Frag 176-191
  • Cytoplamsmic Protein 9.5
  • Gracile Axonal Dystrophy

It has been shown to stimulate lipolysis, slow the process of lipogenesis, and exhibit antibiotic tendencies that are consistent with antigen binders.

Fragment 176-191 5mgHow Fragment 176-191 Functions

According to scientific study that has been conducted on animal test subjects, Fragment 176-191 functions by essentially mimicking the secretions that essentially control fat metabolism.  However, the peptide has been shown to do so without creating the adverse affects that may otherwise happen in relation to blood sugar or cell proliferation.  Because it can seize regulatory control of fat metabolism, it has been shown that it promotes the breaking down of body fat, promotes energy expulsion, boosts fat oxidation, and even elevates muscle mass.

Why Fragment 176-191 Functions

Scientific study based on animal test subjects has determined that Fragment 176-191 can function in this manner because it has an interactive relationship with the cytoplasm and the endoplasmic reticulum membrane that can be found within each cellular unit in an animal test subject.  Fragment 176-191 works in conjunction with these two components to stimulate the ubiquitin-protein hydrolase involved in processing ubiquitinated proteins and ubiquitin antecedents.  This enzyme will in turn mark the peptide bond at the glycene C-terminal of ubiquitin.  Also, the peptide may bond to an unfettered monobiquitin in order to inhibit the degradation of lysosomes; the cell organelle that is chiefly responsible for breaking down waste materials and other cellular debris.

What These Processes Mean

Scientific study that has been based on animal test subjects has shown that Fragment 176-191 can be hypothetically linked to a host of different benefits.

  • The first hypothetical benefit that has been linked relates to the process of lipolysis; that is, the breakdown of adipose tissue, also known as body fat.
  • According to scientific study that has been built on animal test subjects, it has been determined that the presence of the peptide can allow for a rate of lipolysis to occur 12.5 times stronger than the rate when the peptide is not present.
  • This then leads to a significantly more efficient rate of fat burning.
  • Furthermore, it was determined that Fragment 176-191’s elevated process of lipolysis was not associated with any negative side effects, which sets the peptide apart from other peptides that have been shown to function in a similar manner.

Another benefit that has been theorized relates to Fragment 176-191’s association with brain membranes.  Specifically, scientific study based on animal test subjects has derived the notion that the presence of the peptide can play a key role in the treatment or even the prevention of Parkinson’s disease and Alzheimer’s disease.  The reason for this concept is due to the fact that the neuroendocrine systems of those that suffer from Parkinson’s or Alzheimer’s have been shown to have down-regulated versions of Fragment 176-191.  Thus far, it has been thought that the presence of Fragment 176-191 may act to offset the toxicity of the protein malfunctions that have been shown to promote the onset of Alzheimer’s.  Furthermore, it has been hypothesized that the presence of the peptide may be able to prevent the type of basal lesion that have been shown to contribute to the onset of Parkinson’s disease.

Insulin’s Reaction to Fragment 176-191

Scientific study that has been conducted on animal test subjects has also determined that there may be a link in the way in which Fragment 176-191 functions and the pancreas-secreted peptide insulin.  These particular studies have indicated that the presence of the peptide have increased the levels of blood glucose in animal test subjects over a short period of time, and it allowed an animal test subject to experience a longer lasting increase of insulin levels in their plasma.  These particular findings allowed researchers to show how amino acids work together in order to improve insulin travel regulation as a means to achieve a certain level of homeostasis.  What’s more, these studies on insulin demonstrated that a peptide like Fragment 176-191, which is determined to be bioactive in nature, can remain fully operational with a minimum of the proper informational sequence.

PDF View/Download

What is CJC-1295 No DAC?

The tetrasubstitued peptide CJC-1295 No DAC has a chemical structure of C152H252N44O42 and a molecular weight of 3367.2.  Its structure is that of a 30 amino acid peptide chain.  Its functionality is marked by its ability to bioconjugate with the globular protein serum albumin; this means that contains an ability to pair up two biomolecules in order to form a chemical bond.

CJC-1295 No DAC’s Relationship with GHRH1-29

CJC-1295 NO-DAC 2mg (MOD GRF 1-29)According to scientific study that has been based on animal test subjects, it has been determined that CJC-1295 No DAC’s overall functionality and mechanics has been linked to an active agent found within the peptide chain GHRH1-29.

Basically, GHRH1-29 is a prime component of the negative feedback loop that is located within the growth hormone axis of animal test subjects.  This process essentially acts as a means of regulatory control over a host of endocrine system-related processes, thus enabling an animal test subject the ability to maintain a consistent level of homeostasis.

The main issue with GHRH1-29 is that its inherent properties are not long lasting.  This is due to the fact that it has a very rapid half-life; one that lasts less than seven minutes.  The culprit behind this extremely short half-life is an enzyme known as dipeptidyl amino peptidase IV, or DPP-IV.  This particular peptide functions by stimulating the production of antibodies and is essentially associated with processes tied to immune system regulation, signal transduction, and apoptosis (that is, programmed cell death).  Because of the way in which DPP-IV functions, the enzyme more or less causes GHRH1-29’s half-life to cease rather quickly.

However, CJC-1295 No DAC’s relationship with GHRH1-29 essentially subdues DPP-IV’s half-life terminating effects, thus allowing GHRH1-29 to experience an uptick in bioavailability as well as a dramatic increase in half-life – one that lasts for over seven days.  This extension enables the growth hormone axis within an animal test subject to experience a greater interval of production, which in turn allows the animal test subject to experience a more efficient means of homeostasis.  This process is also linked to a few other aspects of CJC-1295 No DAC’s functionality, including its ability to block methionine oxidation and lower levels of deconstruction relating to the amino acid asparangine.

CJC-1295 No DAC’s Functionality and Boosted Processes

According to scientific study that has been built around animal test subjects, it has been determined that CJC-1295 No DAC and its relationship with GHRH1-29 can be linked to several elevated processes.  Some of these boosted processes include:

  • Elevated protein synthesis – scientific study on animal test subjects has determined that CJC-1295 No DAC’s ability to extend the half-life of GHRH1-29 and therefore allow for a greater functionality regarding the growth hormone axis in animal test subjects has led to the thought that a longer interval of cellular receptor engagement can occur, which in turn can cause more proteins to be produced.
  • A reduction of adipose tissue, or body fat – CJC-1295 No DAC’s overall mechanics has demonstrated a capacity to promote the process in which lipids are broken down.  Because of this accelerated degradation of lipids, it has been determined that body fat can be burned through on a significantly more efficient basis.
  • An elevation in the growth of muscular tissue – Because it has been determined that CJC-1295 No DAC can produce an increased proliferation of proteins, scientific study based on animal test subjects has determined that the peptide can influence a greater influx of muscle cells.  This then leads to an increase in muscle mass and size amongst animal test subjects.
  • An expedited recovery from injury – CJC-1295 No DAC’s ability to boost protein synthesis is also thought to enable animal test subjects to heal from various injuries on a more efficient basis.
  • An improved instance of deep sleep – Scientific study based on animal test subjects have determined that the process of protein synthesis reaches its apex when the test subject experiences its deepest level of sleep.  Because of this, it is thought that an animal test subject will be able to experience an enhanced measure of deep sleep as a means to provide compensation for the elevated process of protein synthesis.
  • Boosted bone density – Scientific study based on animal test subjects has determined that CJC-1295 No DAC enables an increased measure of generation regarding bone mineral manner per square centimeter.  This in turn allows for stronger bones that are less susceptible to fractures, breaks, and other bone-related issues.

All matters of research relating to the way in which CJC-1295 No DAC operates has all been culled from scientific study on animal test subjects.  Because of this, any observations relating to CJC-1295 No DAC’s overall functionality should exclusively be the product of study performed in a strictly contained environment such as a medical research facility or a laboratory.

PDF View/Download

What is CJC 1295 with DAC?

The tetrasubstitued peptide CJC 1295 with DAC has a molecular formula of C152H252N44O42, and a molecular weight of 3368.7.  Its structural integrity is composed of 30 amino acids.  Its overall functionality has been marked by its ability to bioconjugate with the globular protein serum albumin, which in turn leads to an advanced level of homeostasis within an animal test subject.

The Interactions with CJC 1295 with DAC

According to scientific study that has been based on animal test subjects, it has been determined that CJC 1295 with DAC’s inherent functionality hinges on its interaction with two specific components that are found within an animal test subject’s body:

  • GHRH1-29 – this peptide chain is responsible for regulating the activity of the growth hormone axis of an animal test subject.  Its release is part of a process referred to as a negative feedback loop.
  • DPP-IV – Otherwise known as dipeptidyl amino peptidase IV, this antigenic enzyme is chiefly associated with processes related to immune system regulation, programmed cellular death, and signal transduction.  Its process has been shown to cause GHRH1-29 to experience a rapid half-life that lasts under seven minutes.

CJC 1295 with DAC

It has been shown through scientific study on animal test subjects that CJC 1295 with DAC essentially quells the production of DPP-IV from happening.  This in turn enables it to allow GHRH1-29 to experience a dramatic increase in its half-life; one that allows it to last over seven days.  This elevated stabilization causes the growth hormone axis to experience a greater level of operation, thus enabling an animal test subject to experience a greater level of homeostasis.

Additionally, scientific study based on animal test subjects has determined that CJC 1295 with DAC’s functionality allows it to block methionine oxidation.  This is important to note because this process is considered to be a key factor in contributing to an animal test subject’s aging process.

CJC 1295 with DAC and Elevated Processes

Because it has been shown that CJC 1295 with DAC has the ability to extend the stability and half-life of GHRH1-29 and block the production of DPP-IV, scientific study that has been conducted on animal test subjects has determined that its presence could be at the root of several elevated processes that a test subject may be able to experience.

The biggest of these elevated process ties to an overall elevation in protein synthesis.  Because CJC 1295 with DAC’s functionality essentially causes a greater capacity of function for an animal test subject’s growth hormone axis, it has been determined that the test subject could process a greater amount of proteins over a longer period of time.  This extended process is thought to be a vital component of allowing an animal test subject to maintain an elevated state of homeostasis.  Most of the other benefits that have been built around it via scientific study on animal test subject all trace back to this overarching process.

  • For example, this boost in protein synthesis has allowed scientific study based on animal test subjects to determine that it can increase the rate at which muscular tissue can be grown.  Because of the proliferation of proteins as brought about by protein synthesis, it has been determined that an animal test subject can experience an uptick in the level of muscle size and muscle mass over time.
  • The added level of protein synthesis has been thought to play a vital role in boosting bone density.  Specifically, research based on animal test subjects has noted that the boost can cause a bone’s mineral matter per square centimeter to increase.  This then makes the bones of an animal test subject to be stronger and less vulnerable to breaks, fractures, and other bone-related injuries.
  • The increase has also been shown to potentially play a key role in the reduction of adipose tissue; that is, body fat.  The overall mechanics of CJC 1295 with DAC has been shown to promote lipolysis; the process in which the lipids that eventually form body fat are broken down.  This accelerated degradation of lipids in turn enables the level of body fat to decrease.

It has also been thought that the elevation in protein synthesis can lead to a boosted amount of deep sleep.  The reasoning here is based on the determination that an animal test subject’s peak time of activity related to protein synthesis occurs during deep sleep.  As such, it is thought that the boost in protein synthesis can cause an elevated amount of deep sleep as a means of compensation.

Any findings or observations relating to CJC 1295 with DAC should exclusively be the product of study performed in a strictly contained environment.

PDF View/Download